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Background:   Clobazam was recently approved for Lennox-Gastaut syndrome in the US. There is no 
published review article focused on clobazam therapeutic drug monitoring (TDM) in English. 
Methods: More than two hundred clobazam articles identified by a PubMed search were carefully 
reviewed for information on clobazam pharmacokinetics.  Clobazam is mainly metabolized by a 
cytochrome P450 (CYP) isoenzyme, CYP3A4, to its active metabolite, N-desmethylclobazam. Then, N-
desmethylclobazam is mainly metabolized by CYP2C19 unless the individual has no CYP2C19 activity 
(poor metabolizer, PM).    
Results: Using a mechanistic approach to reinterpret the published findings of steady-state TDM and 
single-dosing pharmacokinetic studies, four different serum clobazam concentration ratios were studied. 
The available limited steady-state TDM data suggest that the serum N-desmethylclobazam/clobazam ratio 
can be useful for clinicians, including identifying CYP2C19 PMs (ratio >25 in the absence of inhibitors). 
There are three possible concentration/dose (C/D) ratios. The clobazam C/D ratio has the potential to 
measure the contribution of CYP3A4 activity to the clearance of clobazam from the body. The N-
desmethylclobazam C/D ratio does not appear to be a good measure of clobazam clearance and should be 
substituted with the total (clobazam+N-desmethylclobazam) C/D ratio. 
Conclusions: Future clobazam TDM studies need to use trough concentrations after steady-state has been 
reached (>3 weeks in normal individuals and several months in CYP2C19 PMs). These future studies 
need to explore the potential of clobazam and total C/D ratios. Better studies on the relative potency of N-
desmethylclobazam compared to the parent compound are needed to provide weighted total serum 
concentrations that correct for the possible lower N-desmethylclobazam pharmacodynamic activity.  
Standardization and more studies of C/D ratios from clobazam and other drugs can be helpful to move 
TDM forward. 




 Clobazam is a benzodiazepine, but it is the only 1,5-benzodiazepine available on the market since 
all other benzodiazepines have a 1,4 structure. Its nitrogen atoms occupy the 1 and 5 position, a keto 
group is placed in the 4 position, and the remainder of the molecule is analogous to diazepam.1 
Benzodiazepines act mainly by binding to γ-aminobutyric acid (GABA)-A receptors and increasing their 
affinity to GABA, and are considered GABA-A allosteric modulators.2 This action probably explains 
their antiepileptic properties.3  
 Clobazam was first approved in Australia in 1970 and then in France in 1974 for anxiety and 
epilepsy.4 Clobazam demonstrated clinical benefit in more than 50 European epilepsy studies which 
reported data on >3000 pediatric and adult patients, 300 of whom were diagnosed with Lennox-Gastaut 
syndrome.1 This led to 2 multicenter randomized clinical trials (RCTs)5,6 for Lennox-Gastaut syndrome 
using a double-blind design, and to the subsequent marketing in the US in October of 2011 for the 
adjunctive treatment of seizures associated with Lennox-Gastaut syndrome.  
 Bentué-Ferrer et al.7 published an excellent review article focused on clobazam therapeutic drug 
monitoring (TDM) in French, but there is no published clobazam TDM review article in English. In their 
very comprehensive review of the TDM literature on psychiatric drugs, Hiemke et al.8 provided very 
limited information on clobazam TDM, which is only listed in a table. In a TDM practice guideline for 
antiepileptic drugs, Patsalos et al.9 provided information on clobazam using the traditional TDM 
approach. The current review article is based on a comprehensive reading of old and recent literature and, 
more importantly, uses a mechanistic approach10-12 to reinterpret the published findings, taking into 
account what we know about clobazam pharmacokinetics. Thus, pharmacokinetic knowledge based on 
the concept of concentration/dose (C/D) ratio13 is used to provide practical recommendations for 
clobazam TDM. Four different serum concentration ratios are used to interpret clobazam 
pharmacokinetics in TDM: The N-desmethylclobazam/clobazam plasma concentration ratio, the 
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Articles for this review were obtained from a PubMed search completed in January 2012 and then 
updated in April 2012. The search had no time limit and used the word “clobazam”. The first author 
reviewed all abstracts and selected all relevant articles to be read. Moreover, all article bibliographies 
were carefully reviewed for additional important articles not found in the PubMed search. The first author 
completed this computer search in the context of developing a practical guideline for the use of clobazam 
in epilepsy as he has done with all antiepileptic drugs marketed in the US.14 Thus, the original computer 
search included all available clobazam articles, not only those focused on TDM or pharmacokinetics. 
More than two hundred clobazam articles were carefully reviewed. Only those relevant to TDM are 
included in this review article.     
Clobazam pharmacokinetics is characterized by two peculiarities: 1) it has an active metabolite; 
and 2) it is mainly metabolized by two cytochrome P450 (CYP) isoenzymes, CYP3A4 and the 
polymorphic CYP2C19.   
  A drug plasma concentration-to-dose (C/D) ratio is calculated by dividing the drug trough 
steady-state concentration by the dose that the patient is taking. In the opinion of the authors, the C/D 
ratio may be extraordinarily helpful in moving TDM forward, but this concept has suffered from too little 
representation in the literature. There are no comprehensive reviews of the application of this concept to 
TDM. According to a PubMed search, it was first used in a published research article in 1975.15 The C/D 
ratio has frequently been used by researchers working in TDM. Unfortunately, although their research has 
been published in journals like this one, or others with an interest in TDM and/or pharmacokinetics, the 
C/D ratio concept is not usually described in pharmacological textbooks16 or in comprehensive textbooks 
focused on pharmacokinetics.17  
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The C/D ratio, which can be considered a proxy of drug clearance, is at the core of a new family 
of pharmacokinetic mathematical models whose empirical and theoretical adequacy has been 
demonstrated in a number of studies.18,19 Although there is no room in this article to describe these 
models, which are essentially statistical random-effects linear models of steady-state drug concentrations, 
computer simulations and statistical theory have shown that clinical procedures for drug dosage 
individualization designed with these models may outperform some traditional procedures used in 
TDM.18  
The C/D ratio is inversely related to drug clearance; thus, a high C/D ratio indicates poor drug 
clearance and a low C/D ratio indicates rapid clearance. In addition, basic compartmental theory predicts 
that, for a fixed dose, the C/D ratio obtained from TDM studies is directly proportional to the area under 
the curve (AUC0-∞), the typical measure of drug exposure used in single-dose pharmacokinetic studies. 
Although empirical data are needed to better study this relationship, a high AUC should be associated 
with a high C/D ratio and a low AUC should be associated with a low C/D ratio, bearing in mind that 
comparing C/D ratios and AUCs requires comparable doses. 
 
LITERATURE REVIEW 
 The information was classified into five major topics: clobazam metabolism, clobazam versus N-
desmethylclobazam activity, clobazam and N-desmethylclobazam half-lives (Table 1), TDM issues 
(Table 2), and the use of serum concentration ratios to interpret clobazam pharmacokinetics in TDM. 
Four serum concentration ratios are used to interpret clobazam metabolism: the N-
desmethylclobazam/clobazam ratio (Table 3), which is the most established ratio in the literature, and 
three C/D ratios: clobazam C/D ratio (Table 4), N-desmethylclobazam C/D ratio (Table 5), and the total 
clobazam C/D ratio (Table 6). The total clobazam C/D ratio is calculated by dividing the sum of plasma 
clobazam and N-desmethylclobazam concentrations by the dose. These four sections reviewing serum 
ratios on steady state TDM studies are supplemented with the review of the analogous AUC ratios in 




 According to the prescribing information20 and in vitro study,21 clobazam is mainly metabolized 
by N-demethylation through CYP3A4 and, to a lesser extent, by CYP2C19 and CYP2B6. Thus, for 
clinical purposes, one can consider that CYP3A4 is the demethylation pathway that is clinically relevant.  
Another minor clobazam pathway is hydroxylation by CYP2C18 and CYP2C19.21 The main metabolite, 
N-desmethylclobazam (or norclobazam) is mainly hydroxylated by CYP2C1921,22 as long as this CYP is 
present, since a functional enzyme is absent in CYP2C19 poor metabolizers (PMs).  In their in vitro 
study, Giraud et al.21 indicated that CYP3A4 may have a minor role in hydroxylation of N-
desmethylclobazam.  Clobazam drug-drug interaction (DDI) studies using inhibitors and inducers allow 
exploring how changes in CYP3A4 and CYP2C19 activity influence different C/D ratios.  
 According to the prescribing information, mild and moderate hepatic impairment is not associated 
with relevant pharmacokinetic changes. However, clinicians should be careful by using lower initial 
dosing, slower titration and caution before reaching maximum doses.20  
 
Renal elimination. N-desmethylclobazam and its metabolites comprise approximately 94% of the total 
drug-related components in urine;20 thus renal impairment may have some effects on clobazam metabolite 
clearance. According to the prescribing information, the effect of renal impairment on clobazam 
pharmacokinetics was evaluated by administering multiple 20 mg/day doses of clobazam in six patients 
with mildly decreased (> 50 to 80 mL/min) and moderately decreased (30 to 50 mL/min) creatinine 
clearance, and six matching healthy controls. There were small increases in the AUC (<13% for clobazam 
or N-desmethylclobazam) associated with these levels of renal impairment. Thus, no dose adjustment is 
required for patients with mild or moderate renal impairment. According to the prescribing information, 
there are no clobazam studies in patients with severe renal impairments or end-stage renal disease.20 
Roberts and Zoanetti23 found that serum concentrations did not reach toxic levels in a patient with end-




CYP3A4. CYP3A4 is responsible for most CYP3A-mediated drug metabolism but the minor isoforms 
CYP3A5, CYP3A7 and CYP3A43 also can contribute.24 Since there is no data indicating that the minor 
isoforms are relevant for clobazam metabolism, this section focuses only on CYP3A4.  CYP3A4 is the 
most important CYP enzyme in the liver and gut; and there is limited understanding of how its different 
genetic variations contribute to its function. However, there is definitive agreement that there are no 
CYP3A4 PMs.25,26   
 There is also definitive agreement that environmental factors such as inducers and inhibitors have 
major effects on CYP3A4 function.  Some antiepileptic drugs (carbamazepine, phenobarbital and 
phenytoin) and rifampin are major CYP3A4 inducers.13,27 Erythromycin (and some related compounds), 
ketoconazole (and some related compounds) and nefazadone are major CYP3A4 inhibitors.13,27 A 
potential confounder in CYP3A4 studies is that CYP3A4 shares substrates, inhibitors and inducers with 
p-glycoprotein, making it difficult to distinguish the metabolic contributions of CYP3A4 and p-
glycoprotein for a particular drug.  
 There is also information that personal characteristics such age, gender and pregnancy may 
influence CYP3A4 activity.  Neonates and infants have lower CYP3A4 activity but children from 1 to 12 
years of age have greater CYP3A4 activity than adults.28 Geriatric age does not appear to decrease 
CYP3A4 activity.29 On average, females may have 20-50% higher activity than males30 but this may be 
explained by differences in p-glycoprotein rather in CYP3A4 activity.31 Pregnant women may have 
increased CYP3A4 activity.32  
 
Clobazam auto-induction. In vivo controlled studies indicate that clobazam increases the metabolism 
of the CYP3A4 substrate midazolam, since it:  (1) decreases midazolam AUC by 27%, and (2) 
increases the AUC of the metabolite 1-hydroxymidazolam by 4-fold.33 The prescribing information 
provides conflicting information on the clinical relevance of the CYP3A4 induction by clobazam since 
it states that “this level of induction does not call for dosage adjustment of drugs that are primarily 
metabolized by CYP3A4”, but then states that the addition of clobazam may be associated with the 
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loss of contraceptive efficacy, and non-hormonal forms of contraception are recommended when using 
clobazam.20  
 If clobazam is both a mild CYP3A4 inducer and is metabolized by CYP3A4, then one can 
predict some auto-induction in patients not taking powerful CYP3A4 inducers. This happened in one 
study in healthy volunteers34 (see subsection on auto-induction in the section on clobazam C/D ratio).      
 
CYP2C19.The CYP2C19 gene encodes for S-mephenytoin hydroxylase.  The most frequent allele is 
CYP2C19*1, which has normal enzyme activity.35 The two most common allelic variants are 
CYP2C19*2 and CYP2C19*3, which result in a nonfunctional enzyme. The CYP2C19*2 allele is 
particularly frequent in East Asians; approximately 10%-25% of Asians are classified as CYP2C19 PMs 
with two nonfunctional alleles, while fewer than 5% of people from other ethnic backgrounds are 
classified as CYP2C19 PMs.35 In a large US study,36 CYP2C19 PM prevalence was 2.2% in Caucasians 
(95% confidence interval, CI, 1.6%-2.5%) and 4.0% in African Americans (CI 2.6%-6.1%).  Being an 
East Asian with poor tolerance to usual diazepam doses may reflect a CYP2C19 PM genotype.37,38 A new 
CYP2C19 *17 allele has been described and may be associated with the ultrarapid metabolizer phenotype 
for CYP2C19 drugs.39 In 146 Swedes, the prevalence of homozygous subjects (*17/*17) was 2.7%.39 
There are no published studies of the effects of this new CYP2C19 allele in clobazam metabolism. 
  According to the prescribing information, N-desmethylclobazam AUC was approximately 3-5 
times higher in CYP2C19 PMs and 2 times higher in subjects with only 1 active allele than in subjects 
with 2 active alleles.20 The prescribing information makes two statements that may be somewhat 
contradictory:  (1) systemic exposure of clobazam is similar for both CYP2C19 PMs and non-PMs, and 
(2) clobazam dosage in known CYP2C19 PMs may need to be adjusted. Their practical recommendation 
is that in adult patients known to be CYP2C19 PMs, the starting dose should be 5 mg/day instead of 10 
mg/day, and dose titration should proceed slowly up to 20 mg/day and be based upon clinical response. 
An additional titration to the maximum dose of 40 mg/day may be started on day 21.20  
 There is limited independent information on how CYP2C19 polymorphism influences clobazam 
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antiepileptic response. Seo et al.40 published a retrospective Japanese study including 25 PMs, 44 subjects 
with only 1 active allele, and 41 subjects with 2 active alleles. The respective response rates (defined as 
seizure reduction ≥50%) were 65%, 47% and 33%. The odds ratio (OR) of response comparing PMs 
versus subjects with 1 active allele was 10.0 (95% CI, 2.5-39.6) and when comparing those with 1 active 
allele versus those with 2 active alleles it was 2.5 (0.88-7.3). Adverse drug reactions (ADRs) were 
increased in PMs, who had 64% versus 43% in those with 1 active allele and 39% in those with 2 active 
alleles, although these differences were borderline significant (p=0.07). This is consistent with clobazam’s 
description as a drug with wide therapeutic range.10 Therefore, higher levels of N-desmethylclobazam in 
CYP2C19 PMs may be associated with a better chance of response but some risk of increased ADRs.  On 
the other hand, there are two published cases41,42 of severe signs of clobazam intoxication in CYP2C19 
PMs (see Table 2). In these 2 patients, N-desmethylclobazam had extraordinarily long-half lives. One of 
them still had serum N-desmethylclobazam concentrations in the therapeutic range 20 days after clobazam 
discontinuation,42 and the other required complete clobazam discontinuation for 10 days to reduce serum 
concentrations by one-third.41 Both cases appear to have been treated with dosages in the usual 
recommended ranges, but they were too high for these specific patients, which may have led to saturation 
of N-desmethylclobazam metabolism. 
 There is definitive agreement that environmental factors such as inducers and inhibitors have 
major effects on CYP2C19 function in those subjects who are not CYP2C19 PMs and who have some 
CYP2C19 activity present.  In CYP2C19 PMs, inducers and inhibitors may have effects on drugs mainly 
metabolized by CYP2C19 isoenzyme by influencing other metabolic enzymes. Some antiepileptic drugs 
(carbamazepine, phenobarbital and phenytoin) and rifampin are considered CYP2C19 inducers.43.44 
Fluconazole, fluvoxamine, isoniazid, omeprazole and ticlopidine are major CYP2C19 inhibitors.43,45 
Among antiepileptic drugs,44 felbamate is a potent CYP2C19 inhibitor (and CYP3A4 inducer) and 
topiramate and oxcarbazepine are weak CYP2C19 inhibitors (and weak CYP3A4 inducers). Phenytoin is 
a powerful CYP3A4 inducer but may also compete with drugs metabolized by CYP2C19.  Phenytoin is 
metabolized by CYP2C9 and CYP2C19 and follows non-linear kinetics. When serum phenytoin 
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concentrations are high (close to 20 µg/mL), there is probably a particularly high risk of competitive 
inhibition.  This may be relevant to clobazam prescription. According to in vitro studies, N-
desmethylclobazam is a weak CYP2C9 inhibitor35 and competitive inhibition of CYP2C19 is possible, 
too. Haig et al.46 tested N-desmethylclobazam as an antiepileptic drug in 4 patients taking phenytoin. In 2 
of these 4 patients, there was a 1.6-fold increase in phenytoin levels. Thus, it is not surprising that Zifkin 
et al.47 described 3 cases of phenytoin toxicity after adding clobazam to phenytoin therapy in patients with 
relatively high phenytoin levels.  As clobazam sometimes can competitively inhibit phenytoin 
metabolism, some articles suggest that phenytoin sometimes can competitively inhibit clobazam 
metabolism.48  
 Personal characteristics such as age, gender and pregnancy may influence CYP2C19 activity.  
Neonates and infants have lower CYP2C19 activity but children from 1 to 12 years of age have CYP2C19 
activity similar to that of adults.28 Geriatric age does not appear to decrease CYP2C19 activity.29 It is not 
clear whether there are gender differences in CYP2C19 activity.30 Pregnant women may have decreased 
CYP2C19 activity.32 
 
Clobazam versus N-desmethylclobazam activity 
 There is definitive agreement that N-desmethylclobazam has antiepileptic activity.46 What is not 
clear is how much of the clinical activity of clobazam is due to the presence of the metabolite in the 
body. The prescribing information20 reported that the relative potency of N-desmethylclobazam 
compared to the parent compound ranges from 1/5 to equal potency. This estimation was based on 
animal and in vitro receptor binding data but no studies were provided as reference.  
 To determine the clinical relevance of N-desmethylclobazam one needs to know the differences 
between clobazam and N-desmethylclobazam in: (1) pharmacodynamic activity, (2) brain entrance and 
(3) tolerance.  
 Two in vitro pharmacodynamic studies have been published.49,50 Using a whole-cell voltage-
clamp recordings on cultured rat cerebral neurons, Nakamura et al.49 found that the same concentration 
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of clobazam and N-desmethylclobazam displayed approximately similar effects of increasing chloride 
currents. After obtaining cells that express recombinant GABA-A receptors, Fisher et al.50 used whole-
cell voltage-clamp recordings and found that clobazam had approximately twice the potency of N-
desmethylclobazam.  
  Any possible differences in brain entrance between clobazam and N-desmethylclobazam may 
produce differences between the N-desmethylclobazam/clobazam concentration ratios in brain and 
serum.   If there are no differences in the abilities of clobazam and N-desmethylclobazam to cross the 
blood-brain barrier, the serum N-desmethylclobazam/clobazam ratio should be the same as that of the 
brain. There are no published studies on clobazam brain entrance. From a theoretical point of view, the 
ability of a compound to cross the blood-brain barrier is influenced by the drug’s physicochemical 
properties, which determine passive diffusion and/or actions of transporters such as the p-
glycoprotein.51 Particularly in the benzodiazepines, brain uptake may be more closely related to 
lipophilicity.52 According to prescribing information, clobazam and N-desmethylclobazam are p-
glycoprotein substrates20 but data on their affinity is not provided.  P-glycoprotein affinity for clobazam 
and its metabolite may be important, since p-glycoprotein affinities explain differences in other 
psychiatric drugs.  A relevant drug is risperidone, in which the high affinity of p-glycoprotein for the 
main risperidone active metabolite may explain why the metabolite has lower ability than risperidone to 
penetrate the brain and lower activity level.53 Laux et al.54 studied serum and cerebrospinal fluid (CSF) 
concentrations in 2 patients taking repeated doses of clobazam and found that, similar to what is 
observed in serum, there were greater CSF concentrations of N-desmethylclobazam than clobazam. The 
N-desmethylclobazam/clobazam ratios in serum and CSF were roughly similar in each patient. One 
patient had serum and CSF ratios of 10.7 and 8.6, respectively, and the other of 3.3 and 2.7. These 
limited data from 2 patients suggest that the CSF follows the same pattern as serum, and that both 
compounds may have roughly similar brain entrance rates. 
As different species have different metabolic activity and different clobazam metabolites,55  in 
vivo animal studies cannot provide definitive conclusions about the relative contribution of clobazam and 
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N-desmethylclobazam to clobazam antiepileptic activity in humans. N-desmethylclobazam is a minor 
metabolite in rats but is important in mice and guinea pigs.56 Animal studies attempting to extrapolate the 
antiepileptic contributions of clobazam and N-desmethylclobazam to humans need to account for 
differences in metabolism and brain entrance between humans and other species. 
Haigh et al.46, based on their limited clinical experience46 with N-desmethylclobazam 
administration and an animal study57, proposed that N-desmethylclobazam may be less prone to cause 
tolerance. To avoid the contamination of human pharmacodynamic studies by a difference in tolerance 
between clobazam and N-desmethylclobazam, these studies should be completed when the maximum 
tolerance has been acquired.    
Once the relative pharmacodynamic activity under conditions of maximal tolerance and brain 
entrance of clobazam and N-desmethylclobazam are better established, an attempt can be made to 
calculate weighted serum concentrations to better predict clinical response.58 For example, let us assume 
that clobazam has 3 times as much ability to penetrate the blood-brain barrier and is 2 times more potent 
in pharmacodynamic activity. This means that clobazam will be 6 times more potent at brain GABA-A 
receptors (3 times due to greater brain entrance, multiplied by 2 times due to its pharmacodynamic 
activity at the receptors). Therefore, weighted total clobazam serum concentrations should be calculated 
by adding clobazam to one-sixth of N-desmethylclobazam concentrations and may better reflect clobazam 
clinical activity. Obviously, this total serum clobazam concentration would reflect average effects since it 
is possible that genetic, environmental and personal factors may differentially influence clobazam and N-
desmethylclobazam brain entrance and/or action at the GABA-A receptors in different individuals.”  
 
 
Clobazam and N-desmethylclobazam half-lives 
 According to the prescribing information, the estimated mean elimination half-lives of clobazam 
and N-desmethylclobazam were 36-42 hours and 71-82 hours, respectively.20 No details were given on 
how these estimations were obtained. Recent half-life estimations from single and repeated dose studies,33 
required for marketing clobazam in the US, are described in the upper panel of Table 1.  
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 Nine prior studies34,59-67 estimated half-lives in healthy volunteers after single doses of clobazam.  
All 9 studies provided half-lives in non-elderly adults lower than the lowest limit (36 hours) described by 
the package insert, which probably reflects the difficulties of using single-dose studies to estimate half-
lives, and that different methods of calculating half-lives may provide different results. These studies did 
not report subject races. However, all studies were probably done with Caucasians since all were done in 
the US or European countries. In Caucasians, one should expect a low prevalence (around 2%) of 
CYP2C19 PMs.  The recent pharmacokinetic studies by the manufacturer33 excluded CYP2C19 PMs. The 
9 prior studies included a total of 82 individuals, which may incorporate 1 or 2 CYP2C19 PMs. Only 1 
study62 included an individual with a very long N-desmethylclobazam half-life, 131 hours, which is 
consistent with a CYP2C19 PM profile.  
 One study34 provided data from both healthy controls and patients (Table 1). Patients had lower 
clobazam half-lives. No data on co-medications in patients was provided, but the results in patients were 
probably contaminated by inducers. In a single-dose study, Monjanel-Mouterde et al.60 demonstrated 
differences in clobazam half-lives between volunteers and patients with hepatic impairment, but N-
desmethylclobazam was not studied.  
 Clobazam is taken by epileptic patients in repeated doses; thus, studies using repeated dosing 
provide a better idea of what the half-lives of clobazam and N-desmethylclobazam are in a clinical 
environment.  Pharmacokinetic textbooks usually state that 5 half-lives provide approximately 95% of 
steady-state concentrations and 7 half-lives provide 99% of them.68 Most TDM articles consider 5 half-
lives69 to be required before reaching steady state but if one is a strict pharmacologist, one would ask for 7 
half-lives to reach steady state. As a matter of fact, the graphic representation of clobazam TDM in two 
studies suggested that it may take up to 7 half-lives to reach a plateau. The two studies included one by 
Rupp et al.64,65 who gave 20 mg/day (10 mg twice daily) of clobazam for 28 days to 10 Indian subjects 
and one by Ochs et al.61  who gave 10-mg/day clobazam doses for 22 days (5 mg twice a day) to 13 
healthy volunteers.  In the first study,64,65 it was obvious that clobazam reached a steady state within 1 
week in the average patient, but reaching N-desmethylclobazam steady-state took more than 3 weeks. 
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Assuming that 7 half-lives are needed to reach a steady state, if clobazam reached steady state within 1 
week but N-desmethylclobazam required more than 3 weeks, then clobazam behaves with a mean half-
life < 1 day (<24 hours) in a clinical environment, although clobazam may have a mean half-life > 3 days 
(>72 hours).  In the second study,61 on average, clobazam concentration reached a plateau in less than 7 
days while N-desmethylclobazam did not appear to reach a plateau until 3 weeks had passed.  In this 
second study, the clobazam accumulation half-life was about 24 hours. 
 Ochs et al.61 provided gender stratification. The arithmetic mean clobazam accumulation half-life 
was 24.5 hours in 6 males (range, 23.0-35.3) and 24.0 hours in 7 females (range, 21.6-27.4). The 
arithmetic mean N-desmethylclobazam accumulation half-life was 106 hours; according to these long 
half-lives, 3 weeks may be needed to reach steady state of both the compound and active metabolite. In 
this second study, some gender differences appeared to be present in N-desmethylclobazam half-lives, 
with 79.2 hours in 6 males (range, 39.0-108.0) and 128.6 hours in 7 females (range, 44.0-289.0). It is 
possible that female subjects may have included at least 1 CYP2C19 PM with a very long-half life of 289 
hours after repeated dosing. 
 The above half-life estimations are from patients not taking CYP2C19 inhibitors. It is not clear 
how much these estimations are contaminated by rare individuals with a CYP2C19 PM phenotype.  If one 
assumes that a patient without CYP2C19 activity due to genetic reasons or complete inhibition has N-
desmethylclobazam half-lives of 130 hours (or  >5 days) in a single-dose study and of 289 hours (or  >12 
days) in a repeated-dose study, then the patient requires more than 1 month to reach steady-state. 
 In a single-dose study, Greenblatt et al.59 demonstrated differences in clobazam half-lives 
between elderly and young male adults. They70 completed a repeated-dose study of the same patients 
which supported the concept that elderly males have higher clobazam and desmethylclobazam half-lives 
(Table 1), with an average of 326 hours (>13 days) for elderly males. If this estimation is correct, elderly 




Relevance of half-lives for interpreting clobazam DDI studies. Data from the manufacturer33 comparing a 
40-mg single dose versus 40 mg once a day for 15 days in 18 healthy volunteers suggest the inadequacy 
of single-dose studies. When moving from a single dose to repeated dosing for 2 weeks, the drug 
exposure (AUC) increases by 2.5- to 4.5-fold for clobazam and by 20- to 60-fold for N-
desmethylclobazam. This statement from the company probably undervalues the level of underestimation 
of N-desmethylclobazam AUC by single-dose studies, since 2 weeks is probably not enough to reach a 
steady state of serum N-desmethylclobazam concentrations. Thus, any DDI study using single clobazam 
doses carries a major risk of seriously underestimating DDI effects on clobazam metabolism, particularly 
on serum N-desmethylclobazam concentrations.   
 
Relevance of half-lives for interpreting lack of clobazam sedation in single-dose studies. Several 
neuropsychological studies using single doses to study healthy controls indicate that clobazam seems no 
different than placebo and produces less impairment than other benzodiazepines.71-77 However, in anxiety 
RCTs that used repeated clobazam dosing and allowed for N-desmethylclobazam accumulation, it was 
not clear that clobazam was better than other benzodiazepines regarding drowsiness.78  
 Pharmacokinetic studies using single and repeated doses indicate that single-dose experiments 
allow elucidating clobazam action but lead to little accumulation of N-desmethylclobazam. Ochs et al.61 
provided a graphic representation of sedation in 9 healthy volunteers who took 10-mg/day clobazam 
doses (5 mg twice a day) for 22 days, after which clobazam was discontinued. The maximum average 
score in a sedation scale was not reached after day 22.  In summary, only single-dose studies conclude 
that clobazam is less sedating than other benzodiazepines. These studies did not last at least 3-4 weeks 
and, therefore, did not allow for N-desmethylclobazam reaching steady-state. If one wants to inform 
clinicians about clobazam sedating properties under real-world situations, one should complete studies 




Dosing. In spite of the relatively long clobazam and N-desmethylclobazam half-lives, the prescribing 
information for epilepsy recommends dosing clobazam twice a day.20 The literature does not explain why 
twice a day may be needed since a clobazam half-life of 36 hours would allow for once-a-day dosing. 
 In their review of anxiety RCTs, Brogden et al.79 recommended dosing clobazam 2 or 3 times a 
day for anxiety. They also described a preliminary study indicating that greater decreases in anxiety 
corresponded to clobazam peak values. Thus, it possible that administering clobazam twice a day, which 
provides 2 peaks, will determine potentially greater anti-anxiety effects which occur in the peaks.    
 
TDM issues 
Therapeutic window. Steady-state serum clobazam and N-desmethylclobazam concentrations are 
described as linearly related to dose.9,20 There are no studies of kinetic linearity in CYP2C19 PMs.  
 There is limited information regarding the clobazam therapeutic concentration window or range 
for controlling seizures. A large naturalistic study in children80 provided evidence that clobazam has a 
wide therapeutic window. In a comprehensive review, Patsalos et al.9 stated that (1) because tolerance 
tends to develop to ADRs and sometimes to the therapeutic effects of clobazam, there is no clear 
relationship between efficacy and serum concentrations of either clobazam or N-desmethylclobazam; and 
(2) therapeutic clobazam doses were associated with serum concentrations of 30–300 ng/mL for the 
parent drug and 300–3000 ng/mL for N-desmethylclobazam.  In another review, Neels et al.81 
recommended a clobazam therapeutic range of 100–400 ng/mL, but provided no range for N-
desmethylclobazam.  In a sample of 11 consecutive patients (including many with DDIs), Contin et al.22 
described median serum concentrations of 200 ng/mL (range, 80-560) for clobazam and 1370 ng/mL 
(range, 200-5000) for N-desmethylclobazam. In 39 adults, Guberman et al.82 reported that all 6 patients 
who had ADRs that appeared to be dose-related had plasma concentrations >900 ng/mL for N-
desmethylclobazam.  
 Table 2 describes 6 reports of clobazam intoxication,41,42,83-86 including 2 deaths85,86 that occurred 
at elevated serum concentrations. Four of these cases41,42,84,85 had N-desmethylclobazam concentrations 
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>3000 ng/mL; 3 cases41,42,85 had concentrations  > 4 times 3000 ng/mL, including 1 case85 >10 times 3000 
ng/mL. N-desmethylclobazam concentrations were not measured in 2 cases,83,86 but their clobazam 
concentrations were >3000 ng/mL or 10 times higher than the upper recommended limit of 300 ng/mL.  
 
Trough versus peak concentrations. Most studies of TDM in antiepileptic drugs tend to use trough levels 
after reaching steady-state to standardize measures. Clobazam literature is contaminated by the use of 
non-trough TDM in many studies. No systematic studies compare trough and peak clobazam 
concentrations in TDM, but Ochs et al.61 provided a graphic representation of clobazam serum 
concentrations of a healthy volunteer after 22 days under 10 mg/day. The trough clobazam concentration 
was approximately 270 ng/mL, and a peak of approximately 400 ng/mL was obtained in less than 2 hours 
after clobazam intake at day 22. Three hours after this intake, the concentration decreased to 
approximately 330 ng/mL. The trough N-desmethylclobazam concentration was approximately 500 
ng/mL, with no obvious change in the 3 hours after the last intake at day 22. After 12 hours, it reached a 
level of approximately 570 ng/mL. This means that N-desmethylclobazam increases less than 15% from 
trough and peaks during the day, but clobazam increases up to 48% from trough to peak during the 2 to 3 
hours after clobazam intake.  
 
Serum concentration ratios to interpret clobazam TDM 
 We propose 4 possible ratios for serum concentrations that may help to interpret clobazam 
concentrations in TDM studies.  The N-desmethylclobazam/clobazam ratio has been studied a few times 
in the literature. The other 3 ratios are different ways of examining C/D ratios. The clobazam C/D ratio 
and the N-desmethylclobazam C/D ratio have occasionally been calculated in published articles. No 
article was found that described the use of the total C/D ratio.  
 Tables 3 to 6 provides data on these 4 ratios extracted from published TDM studies. The footnote 
b of Table 4 provides a clarification regarding units for C/D ratios. Table 7 reviews additional information 




 As clobazam is mainly metabolized by CYP3A4, and N-desmethylclobazam by CYP2C19, the N-
desmethylclobazam/clobazam ratio is influenced by the activity of both CYP enzymes.  Therefore, a high 
N-desmethylclobazam/clobazam ratio can indicate: (1) the presence of a CYP2C19 PM or the co-
prescription of a potent CYP2C19 inhibitor, (2) the co-prescription of a CYP3A4 inducer, or (3) both. 
Table 3 presents a comprehensive review of the few published studies reporting data on the N-
desmethylclobazam/clobazam ratio.21,22, 40,41, 48, 61,64, 69,87-91 The data suggest that:  (1) very high ratios (>25) 
indicate that the patient is a CYP2C19 PM, or is taking a drug which is a CYP3A inducer and a CYP2C19 
inhibitor, such as felbamate; (2) ratios of 10-25 are compatible with the patient taking a CYP3A inducer; 
and (3) ratios <10 are compatible with “normal” patients [who are: (a) not taking CYP3A inducers, (b) 
not taking CYP2C19 inhibitors, and (c) not CYP2C19 PMs]. These ratio ranges are rough approximations 
calculated by reviewing the limited available studies, which were not designed to study this ratio.  In fact, 
none of the articles explored whether there are differences in the N-desmethylclobazam/clobazam ratio 
between children and adults.   
 
CYP3A4 and CYP2C19 inhibitors. There are no steady-state TDM studies on the effects of CYP3A4 or 
CYP2C19 inhibitors on the N-desmethylclobazam/clobazam ratio. Table 7 describes a single-dose study 
by the manufacturer33 that provided mean AUCs after 6 days on ketoconazole (CYP3A4 inhibitor) and on 
omeprazole (CYP2C19 inhibitor). This limited data indicated that ketoconazole mildly decreased this 
ratio (by 24% or multiplying by a factor of 0.76) and omeprazole mildly increased it (by 18% or 
multiplying by a factor of 1.18), which is consistent with pharmacological knowledge. It is possible that, 
under steady-state conditions of both inhibitors and clobazam, these effects may be larger and clinically 






Clobazam C/D ratio 
 The clobazam C/D ratio may be mainly a measure of CYP3A4 activity. Table 4 presents a 
comprehensive review of the few published studies that provided data either peak or trough 
concentrations (see footnote a) that can be used to calculate clobazam C/D ratio.22,41,48,61,69,88-91  
 If the clobazam C/D ratio is a measure of CYP3A4 activity the following predictions can be 
made, it should: 1) be lower in patients taking inducers than in normal controls; 2) change with time if 
clobazam auto-induces its metabolism; 3) be lower in children 1-12 years than in adults; 4) be higher in 
patients taking CYP3A4 inhibitors; and 5) not be influenced by CYP2C19 inhibitors.  
 
Inducers. Table 4 indicates that normal subjects appear to have clobazam C/D <30 while patient takings 
inducers show clobazam C/D ratios <10, which is consistent with greater CYP3A4 activity.  
 The average clobazam concentration decreased by 62% (from 354 to 136 ng/mL)91 in the only 
well-controlled study of induction. This study used subtherapeutic doses of carbamazepine (400 mg/day) 
and a too short (2 weeks) duration to reach maximal induction. Naturalistic studies indicate: 1) patients 
taking phenytoin or carbamazepine had significantly lower C/D ratios corrected by weight;34 2) trough 
weight-corrected clobazam C/D ratio appeared to be 10 times higher in the volunteers than in adult 
patients presumably taking inducers; 34  and 3) no significant differences in clobazam peak concentrations 
were observed before and after carbamazepine administration, but N-desmethylclobazam concentration 
increased significantly.34 In a single-dose study92 measuring AUCs, clobazam clearance was increased by 
carbamazepine and phenytoin (Table 7). 
 
Auto-induction. Bun et al.34,88 compared peak and trough weight-corrected clobazam C/D ratios from 6 
healthy volunteers and 17 patients (6-32 years) with co-medications. In patients who were presumably 
taking inducers, there was a very small increase from day 2 to day 21. It is interesting that in healthy 
volunteers both peak and trough weight-corrected clobazam C/D ratios increased from day 2 to day 7, and 
then decreased to day 21.  In healthy volunteers at day 7, when steady state has not been reached, one 
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would expect that all C/D ratios, clobazam C/D, N-desmethylclobazam C/D and total C/D ratios, should 
be lower than those at day 28. However, it is striking that 5 of 6 patients had clobazam C/D ratios that 
were 20-30% higher at day 7 than at day 28. This is consistent with self-induction, which is manifested by 
decreased clobazam concentrations at day 28 compared to day 7.  
 In a pharmacokinetic study using 10 mg/day of clobazam for 22 days, focused on 12 young and 
12 elderly adults, no signs of self-induction in clobazam metabolism were observed.70    
 
Age. Adults are treated with proportionally lower clobazam doses than children on a weight-normalized 
basis (e.g. mg/kg).40, 65 When studying adult and children dosages, clobazam articles frequently quote a 
study by Tedeschi et al.,66 who compared 16 children with 14 adolescents or adults who had respective 
trough clobazam C/D ratios of 0.078±0.01 and 0.147±0.02 (units were not provided). However, this 
comparison does not take into account the metabolism of N-desmethylclobazam and did not correct for 
the effects of inducers. In a naturalistic study,34 trough weight-corrected clobazam C/D ratios in children 
appeared to be half those in adults.    
 
CYP3A4 and CYP2C19 inhibitors. There are no steady-state TDM studies on the effects of CYP3A4 or 
CYP2C19 inhibitors on clobazam C/D ratios. Table 7 describes a single-dose study by clobazam maker33 
using ketoconazole (CYP3A4 inhibitor) and omeprazole (CYP2C19 inhibitor) that indicates they have 
small effects but it is possible that under steady-state conditions of both the inhibitors and clobazam, these 
effects may be larger and clinically relevant.12  
 In summary, the limited data on clobazam C/D ratio and clobazam AUC suggest that the 
clobazam C/D ratio may have reasonable potential for being a good measure of CYP3A4 activity. 
Children and patients taking inducers appear to have lower clobazam C/D ratios. Patients on CYP3A4 
inhibitors should have higher clobazam C/D ratios. As most epileptic patients taking clobazam are on 
powerful inducers, one should not expect clobazam C/D ratios to be influenced by auto-induction. Auto-
induction may be mild and only seen in individuals not taking powerful inducers.    
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N-desmethylclobazam C/D ratio 
 Bun et al.34 found that peak weight-corrected N-desmethylclobazam C/D ratios were very mildly 
elevated when compared with trough weight-corrected N-desmethylclobazam C/D ratios. This is 
compatible with the findings that 1) N-desmethylclobazam has a very long half–life and 2) there are small 
differences between studies using peaks or trough N-desmethylclobazam measures. Table 5 presents a 
comprehensive review of the few published studies22,41,48,61,69,88-91 that provided data for the N-
desmethylclobazam C/D ratio.  
 The N-desmethylclobazam C/D ratio has been described by some studies. However, it is not a 
good measure because it is influenced by both CYP3A4 and CYP2C19 activity and may not solely reflect 
clobazam clearance. There is no consistent pattern for the N-desmethylclobazam C/D ratio in Table 5. 
Other studies indicate how inducers, age, CYP3A4 inhibitors, CYP2C19 inhibitors and CYP2C19 PM 
phenotype may influence N-desmethylclobazam C/D ratio.   
 
Inducers. In 414 patients from 9 months to 40 years of age, Bun et al.34 measured peak concentrations 
three hours after clobazam morning dose and calculated an N-desmethylclobazam C/D ratio corrected for 
weight. They found that those taking phenytoin or carbamazepine had significantly higher values. In a 
subsample of 10 patients, there were significant differences in N-desmethylclobazam peak concentrations 
before (727 ng/mL) and after (1720 ng/mL) carbamazepine administration (the concentration more than 
doubled). Another study in the same article focused on the comparison of 6 healthy volunteers with 17 
patients (6 -32 years) with co-medications. The trough weight-corrected N-desmethylclobazam C/D ratio 
appeared to be more than twice as high in healthy volunteers as in adult patients. The co-medications 
were not described.  
 Contin et al.89 found that felbamate was associated with 5 times higher weight-adjusted N-
desmethylclobazam C/D ratios.  Jawad et al.92 compared 6 adult controls with 6 adult epileptic patients 
who took a single dose of clobazam on stable phenytoin or carbamazepine doses for 3 months. N-
desmethylclobazam AUC increased by a factor of 5.24 on phenytoin versus a factor of 1.66 on 
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carbamazepine (Table 7).  In a study administering N-desmethylclobazam 30 mg/day for 2 weeks, Pullar 
et al.63 compared 8 healthy controls, 5 female patients and 3 male patients. The male controls had median 
N-desmethylclobazam C/D ratios of 40.5 (ng × mg)/(mL × day) (range 36.7-55). The 5 female patients 
had slightly elevated ratios with a median of 63.3 (ng × mg)/(mL × day) (range 40.3-76.7). All 3 male 
patients were taking phenytoin and had ratios twice as high, with a median of 82.3 (ng × mg)/(mL × day) 
(range 77.6-95.0).   
   
Age. Bun et al.34 provided graphic results for trough weight-corrected N-desmethylclobazam C/D ratios, 
which appeared to be roughly twice as high in adult as in child patients. Co-medication was not described 
and the study included only 17 patients. In a larger sample of 414 patients, trough weight-corrected N-
desmethylclobazam C/D ratios were significantly lower in children than in adults. 
 
CYP3A4 and CYP2C19 inhibitors. There are no steady-state TDM studies on the effects of CYP3A4 or 
CYP2C19 inhibitors on the N-desmethylclobazam C/D ratio. Table 7 describes a single-dose study33 by 
clobazam maker using ketoconazole (CYP3A4 inhibitor) and omeprazole (CYP2C19 inhibitor). This 
limited data indicated that there were almost no increases in the N-desmethylclobazam AUC on 
ketoconazole (12% or multiplied by a factor of 1.12), but there was an important increase on omeprazole 
(65% or multiplied by a factor of 1.65). Under steady state conditions for omeprazole and clobazam these 
effects may be larger.  
 
CYP2C19 PMs. Table 4 describes a few cases with the CYP2C19 PM phenotype who had very high N-
desmethylclobazam C/D ratios. According to the prescribing information,20 CYP2C19 PMs had a 5-fold 
increase in N-desmethylclobazam AUC. 
 In summary, the limited data on desmethylclobazam C/D ratio and desmethylclobazam AUC do 
not show a clear pattern that clearly informs clinicians regarding possible ranges. As expected, the 
CYP2C19 PM phenotype and taking CYP2C19 inhibitors should increase the desmethylclobazam C/D 
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ratio. The limited available information suggests that phenytoin may behave as a CYP2C19 inhibitor in 
some patients, probably due to competitive inhibition with N-desmethylclobazam metabolism.   
  
Total C/D ratio 
 Table 6 presents a comprehensive review of the few published studies that provided data 
pertaining to total C/D ratios. 22,41,61, 69,88, 91 Although little can be concluded from this limited information, 
most normal subjects appear to have total C/D ratios < 100. CYP2C19 PMs appear to have total C/D 
ratios >200. 
 
CYP3A4 and CYP2C19 inhibitors. There are no steady-state TDM studies on the effects of CYP3A4 or 
CYP2C19 inhibitors on the total C/D ratio. Table 7 describes limited data from a single-dose y study33 by 
clobazam maker using ketoconazole (CYP3A4 inhibitor) and omeprazole (CYP2C19 inhibitor). There 
were small increases in the total AUC on ketoconazole (26% or multiplied by a factor of 1.26), but there 
was an important increase on omeprazole (54% or multiplied by a factor of 1.54). Under steady state 
conditions for these inhibitors and clobazam, it is possible that these effects may be larger.  Based on 
pharmacogenetic data, the prescribing information20 states that strong (e.g., fluconazole, fluvoxamine, and 
ticlopidine) and moderate (e.g., omeprazole) CYP2C19 inhibitors may result in up to 5-fold increases in 
exposure to N-desmethylclobazam.  Thus, clobazam dosage adjustment may be necessary when co-
administered with strong or moderate CYP2C19 inhibitors, including omeprazole. 
 Jawad et al.92 compared 6 adult controls with 6 matched adult epileptic patients who had taken 
stable doses of phenytoin or carbamazepine for 3 months and received clobazam single doses. After 
adding clobazam and N-desmethylclobazam AUCs, there were 2 patients taking phenytoin who clearly 
had increased N-desmethylclobazam levels and total AUCs increased by a factor of 3.3, while 
carbamazepine was associated with a very small increase in total AUC (Table 7). 
 In summary, no prior study has calculated total C/D ratios.  The limited data on total C/D ratios 
and total AUCs suggest that the total C/D ratio may have reasonable potential for being a good measure 
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of total clobazam clearance. The CYP2C19 PM genotype and possibly powerful CYP2C19 inhibitors 
may be associated with increased total C/D ratios. There are very limited data on how CYP3A4 inhibitors 
may influence total C/D ratios. The data on inducers are complex. Phenytoin appears to reduce serum 
clobazam concentrations but may increase N-desmethylclobazam concentrations in some patients, more 
dramatically than the reduction in clobazam concentrations.  It is not clear whether carbamazepine 
decreases total C/D ratio or not. 
 
DISCUSSION  
The need for standardization in future clobazam TDM studies 
 The first conclusion drawn from this literature review is that the available pharmacokinetic 
literature on clobazam is limited by the lack of standardization. Future clobazam TDM studies need to use 
both steady-state and trough concentrations. As N-desmethylclobazam has a very long half-life, 3 weeks 
are needed to reach steady-state in normal subjects.  Trough concentrations are fundamental to properly 
interpret clobazam TDM. It does not appear prudent to try to use peak concentrations since, according to 
the limited information available,61 serum clobazam concentrations vary substantially between 2-3 hours 
after a dose.  Some published studies have used blood drawn within 3 hours of administering clobazam 
but these studies cannot determine if each collection corresponds to the time of peak concentration (at 
approximately 2 hours) or after the peak.  Moreover, using peak concentrations requires accounting for 
the fact that food does not influence the extent of clobazam absorption but may slow the absorption 
rate.93,94    
 
Clobazam versus N-desmethylclobazam activity 
 Better studies on the relative potency of N-desmethylclobazam compared to the parent compound 
are needed.95 This is a major requirement to make clobazam TDM a better instrument in the prediction of 
response and ADRs.  Unfortunately, it is not easy to study this issue in a definitive way. In vivo human 
studies combining TDM and brain imaging of GABA receptors after maximal tolerance has been acquired 
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may be needed to definitively explore this issue. Studies combining TDM and brain imaging may provide 
information on the GABA-A binding activity of clobazam and N-desmethylclobazam which would allow 
the establishment of weighted total serum concentrations58 for the average individual and initial 
exploration of interindividual variability. Considerable research studies or even new research approaches 
will be required to personalize clobazam pharmacokinetics and pharmacodynamics according to the 
genetic, environmental and personal characteristics of each individual.    
 
CYP2C19 PM 
 CYP2C19 PMs may require much higher periods to reach a steady state than normal individuals. 
They may take several months to reach this state. Therefore, dose increases in these subjects should be 
extraordinarily slow.  The limited data available from a few intoxicated patients suggest that it is possible 
that CYP2C19 saturation may occur in these subjects when high but therapeutic doses are prescribed. 
Clobazam TDM may be crucial in identifying these subjects. In the absence of CYP2C19 inhibitors, an 
N-desmethylclobazam/clobazam ratio >25 may be suggestive of a CYP2C19 PM genotype. 
 
Therapeutic window 
 The lack of good prospective studies limits our information on clobazam therapeutic range. The 
lack of publication of TDM data from recent RCT trials5,6 on Lennox-Gastaut is a major limitation.  
Tolerance to efficacy and ADRs may also decrease the value of TDM. There is no definitive agreement 
on the relevance of tolerance for clobazam response. Older reviews provide estimations of tolerance 
development ranging from 1/378 to 89%.96 Some recent reviews comment that the problem of tolerance 
may have been overestimated.97,98   
 Currently, the best approximation to a therapeutic window or range is that of Patsalos et al.9 They 
described therapeutic clobazam doses as those associated with serum concentrations of 30–300 ng/mL for 
the parent drug and 300–3000 ng/mL for N-desmethylclobazam.  If a patient on TDM has concentrations 
within these ranges and has not responded, then the patient is not likely to respond to clobazam treatment.  
26 
 
 Clobazam probably has a wide therapeutic window, making only very high concentrations 
relevant to help diagnose toxicity. If there are symptoms consistent with clobazam intoxication, the 
presence of very high concentrations (>3000 ng/mL for clobazam and/or >12,000 ng/mL for N-
desmethylclobazam) probably confirm clobazam intoxication.  
 
N-desmethylclobazam/clobazam ratio 
 The available limited data suggest that the N-desmethylclobazam/clobazam ratio can be useful for 
clinicians. This review suggests that:  (1) very high ratios (>25) indicate that the patient is a CYP2C19 
PM or taking a CYP3A4 inducer and CYP2C19 inhibitor such as felbamate; (2) ratios of 10-25 are 
compatible with the patient taking a CYP3A4 inducer; and (3) ratios <10 are compatible with “normal” 
patients who are:  (a) not taking CYP3A4 inducers, (b) not taking CYP2C19 inhibitors, and (c) not 
CYP2C19 PMs.  
 Although there are no definitive data to support it, phenytoin may frequently behave as felbamate, 
acting simultaneously as a CYP3A4 inducer and CYP2C19 clinically-relevant inhibitor. If this is correct, 
phenytoin may be associated with N-desmethylclobazam/clobazam ratios >25. Based on pharmacological 
knowledge, it is reasonable to predict that potent or moderate CYP2C19 inhibitors such as fluconazole, 
fluvoxamine, isoniazid, omeprazole and ticlopidine may be associated with N-
desmethylclobazam/clobazam ratios >25.  
 Future clobazam TDM studies need to examine the effects of topiramate and oxcarbazepine on 
the N-desmethylclobazam/clobazam ratio. These two drugs are both weak CYP2C19 inhibitors and weak 
CYP3A4 inducers. Unfortunately, the actions of these drugs are not easy to study since the dosing level 
may be significant. It is believed44 that only high doses of oxcarbazepine (≥ 1500 mg/day) or topiramate 
(≥ 400 mg/day) may cause CYP3A4 induction. In low and average doses, only their CYP2C19 inhibitory 





Total C/D ratio 
 The previously published literature does not describe the total C/D ratio. Future studies should 
explore whether it is a good measure to distinguish individuals according to their drug clearance ability. 
From the available knowledge on pharmacological mechanisms, using this ratio may be more reasonable 
than using the N-desmethylclobazam C/D ratio. It is possible that renal impairment associated with aging, 
particularly in males,70 may be associated with high total C/D ratios.  
 
Clobazam C/D ratio 
 The clobazam C/D ratio has potential to measure the contribution of CYP3A4 activity to the 
clearance of clobazam from the body. If this is correct, children (ages 1-12 years) will have decreased 
clobazam C/D ratios after weight correction.  Similarly, individuals taking inducers (carbamazepine or 
phenytoin) will have decreased C/D ratios. Patients taking potent CYP3A4 inhibitors (erythromycin or 
ketoconazole and some related compounds) will have increased clobazam C/D ratios.   
 
CONCLUSION 
This comprehensive review of the clobazam literature found a lack of standardization. Future clobazam 
TDM studies need to use both steady-state and trough concentrations. As N-desmethylclobazam has a 
very long half-life, three weeks are needed to reach steady-state in normal subjects while months may be 
needed in CYP2C19 PMs and elderly males.   
 Using a mechanistic approach to reinterpret the published findings, four different serum 
concentration ratios were studied to interpret clobazam pharmacokinetics in TDM. The available limited 
data suggest that the N-desmethylclobazam/clobazam ratio can be useful for clinicians. This review 
suggests that:  (1) very high ratios (>25) indicate that the patient is a CYP2C19 PM, or taking a drug 
which is a CYP3A inducer and CYP2C19 inhibitor such as felbamate (or possibly phenytoin); (2) ratios 
of 10-25 are compatible with the patient taking a CYP3A inducer; and (3) ratios <10 are compatible with 
“normal” patients.  
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 There are 3 possible C/D ratios. The clobazam C/D ratio has potential to measure the contribution 
of CYP3A4 activity to the clearance of clobazam from the body. The N-desmethylclobazam C/D ratio 
does not appear to be a good measure of clobazam clearance and should be substituted by the total 
(clobazam + N-desmethylclobazam) C/D ratio. Better studies on the relative potency of N-
desmethylclobazam compared to the parent compound are needed to provide weighted total serum 
concentrations that appropriately correct for the possible lower N-desmethylclobazam pharmacodynamic 
activity at the GABA-A receptors.  Standardization and more studies of C/D ratios from clobazam and 
other drugs can be helpful to move TDM forward.  
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Table 1. Clobazam pharmacokinetic studies providing half-life estimations.     
   Sample  Dose                Half-life (hours)    
Reference  size  mg/d Clobazam   N-desmethylclobazam   
RECENT STUDIES BY COMPANY IN HEALTHY ADULT VOLUNTEERS (probably Caucasians) 
SINGLE DOSE 
33Walzer et al.a  18  10   37.5 (17-69)  67.5 (33-133) 
REPEATED DOSE (15 days) 
33Walzer et al.a  18  40   32   57     
OTHER SINGLE-DOSE STUDIES IN HEALTHY ADULT VOLUNTEERS (probably Caucasians) 
34Bun et al.b  6      Unknown 24 (±7c)  57(±33c) 
 
59Greenblatt et al. 7♂young 20 16.6 (11-23)d  Not studied 
   8♀young 20 30.7 (18-46)d  Not studied  
   7♂elderly 20 47.7 (29-77)d  Not studied 
   6♀elderly 20 48.6 (23-72)d  Not studied 
60Monjanel- Mouterde 
   et al.   6♂  20 22 (±6c)e  Not studied   
   
61Ochs et al.   7♂  20 22.3(13.6-35.2)f  Not studied 
   9♀  20 26.0(19.1-33.0)f  Not studied 
 
62Pullar et al.  6♂  30 31 (13-44)g  70(20-131)g 
 
63Pullar et al.  8♂  30 30 (±6.3c)g   64h(±4.3c)g         
 
64,65Rupp et al.   10♂  15-30 18 (9.7-30.3)  Not studiedi 
 
66Tedeschi et al.  6  10 25 (10-57.9)j  Not studied 
 
67Vallner et al.   12♂  10k 18.4   Excluded contributionk 
     20k 18.3   Excluded contributionk 
     40 k 17.3   Excluded contributionk 
                   averagel 23   Excluded contributionk   
SINGLE-DOSE STUDY IN PATIENTS TAKING ANTIEPILEPTIC DRUGS (probably Caucasians) 
34Bun et al.b  Adultsm   12 (±6c)   49 (±38c) 
   Childrenm  16 (±3c)   15 (±2c)    
SINGLE-DOSE STUDY IN PATIENTS WITH HEPATIC IMPAIRMENT (probably Caucasians) 
60Monjanel- Mouterde 6 Acute  20 47 (±18c)e  Not studied       
   et al.       hepatitis         
   9 Cirrhosis 20 51 (±21c)e  Not studied    
REPEATED-DOSE FOR 22 DAYS IN HEALTHY ADULT VOLUNTEERS (probably Caucasians) 
70Greenblatt et al. 7♂youngn 10 22.6 (11-29)o   48.4 (23-92)o  
   8♀youngn 10 35.5 (24-45)o   71.5 (39-116)o  
   6♂elderlyn 10 72.7 (39-106)o  326.0 (67-831)o 
   6♀elderlyn 10 52.0 (20-76)o   68.7 (33-107)o    
aTerminal half-lives were calculated using noncompartmental methods.  
bHalf-lives were calculated by computer program (APIS). 
cRanges were not provided but standard deviations were described. 
dThese are elimination half-lives calculated using iterative non-linear least-squares regression techniques. 
There were no differences in clearance between young ♂ and ♀ suggesting that greater half-lives in ♀ 
were explained by greater volume of distribution.  
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eHalf-lives were calculated by linear regression analysis of the terminal parts of the log plasma 
concentrations versus time curves. 
fThe terminal (smallest) exponent was used to calculate the apparent half-life of elimination. 
gElimination half-life was calculated from the terminal portion of the log10 serum concentration curves. 
hThe authors also studied the same healthy controls after administering 30 mg of N-desmethylclobazam. 
This provided an N-desmethylclobazam half-life of 46.5 (±5.5) hours. 
iThe authors also studied three healthy controls after administering 40 mg of N-desmethylclobazam. This 
provided N-desmethylclobazam half-lives of 36-46 hours.  
jClobazam pharmacokinetics were fitted to a tri-exponential equation associated with a two-
compartmental model using a non-linear regression program.    
kPatients were randomly assigned to 10-, 20- or 40-mg doses at 3 different times. Authors calculated a 
half-life from the terminal phase of the individual curves “after excluding the contribution of the N-
desmethylclobazam”.  
lThe authors used a two-compartment model for calculating the average. 
mThe patient sample included 17 patients (numbers of children and adults were not specified). 
nThe same subjects  who took part in the single-dose study.59 




Table 2. Clobazam therapeutic drug monitoring in cases with intoxication signs.     
   Serum concentration (ng/mL) 
Reference  Clobazam         N-desmethyl-  Type of study Description    
     clobazam        
 
41Aylett et al.   Up to 100 Up to 14400 Case reporta Ataxia & abnormal movements 
              
83Montenegro et al. 3900  Not described 1/251 patientsb Respiratory depression 
                                                               
84Naccarato et al.  Up to 423c Up to 3,302c Case reportd Ataxia and dysarthria 
 
42Parmeggiani et al.    190  14700  Case reporte Severe somnolence 
 
85Pok et al.     720f  36000f  Overdose caseg Death 
 
86Proença et al.   3900f  Unknownh Overdose casei  Death    
aA 4-year-old male developed intoxication signs after adding 15 mg/day (0.75b mg/kg/day) of clobazam  
to lamotrigine. The patient had repeated serum concentration measures and was interpreted as an N- 
desmethylclobazam poor metabolizer (PM). Clobazam was discontinued for 10 days and restarted with a 
dose of 7.5 mg/day. 
bIn a US epilepsy center 251 patients were treated with clobazam. One of them was described as suffering  
from clobazam intoxication; no data is provided on dose or co-medications. 
cThe conversion of μmol/L to ng/mL (for clobazam 1.0 μmol/L=333 ng/mL and for N-
desmethlyclobazam 1.0 μmol/L=349 ng/mL) was based on Patsalos et al.9   
dA 44-year-old male developed intoxication signs after adding an antiretroviral agent, etravirine,  
which is a CYP3A4 inducer and CYP2C19 inhibitor, to antiepileptic treatment of clobazam and valproate.    
eA 10-year-old female developed severe somnolence with increased weight and enuresis. She was  
initially treated with 0.6 mg/kg/day (20 mg/d) and then her dose was decreased to 0.4 mg/kg/day 
(12 mg/d). The patient was thought to be an N-desmethylclobazam PM, possibly a CYP2C19 PM due to 
the presence of a CYP2C19 inactive allele (*2) and possibly a rare undetected CYP2C19 inactive allele. 
Twenty days after discontinuation, she had N-desmethylclobazam concentrations of 6,500 ng/mL while 
clobazam was below the level of detection (<10 ng/mL).This patient appears also to be case report 2 in 
another article.22 
fAccording to Proença et al.86 there is no tissue redistribution after death; thus postmortem blood  
concentrations reflect well the concentrations before death.   
gA 70-year-old French women was found dead. The contribution of other drugs was eliminated by the   
toxicology report.   
hUnable to quantify due to lack of standard.  
iA 49-year-old Caucasian Portuguese female was found dead after an overdose. She also had 
bronchopneumonia, possibly associated with the respiratory depression caused by clobazam. The 
contribution of other drugs was eliminated by the toxicology report. 
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Table 3. Review of articles providing clobazam concentrations: N-desmethylclobazam/clobazam ratio 
Reference  Normal  Inducersa Felbamateb CYP2C19 PM      
          N-desmethylclobazam/clobazam ratio       
41Aylett et al.c         246 
87Bardy et al.  4-5d  20d 
88Bun et al.e   4.6 (N=6)  
   range 2.3-8.4 
89Contin et al.f  3 (N=22) 13 (N=28) 29 (N=16) 
   None >20 One >20 One <20  
22Contin et al.  8 (N=11)g      207.5 (N=1)h & 77.4 (N=1)i   
            
21Giraud et al.  3 (N=18)j 
   6 (N=4)j 
   None >10 
70Greenblatt et al.k 1.5 (N=7♂young)   
   4.3 (N=8♀young) 
              13.8 (N=6♂elderly) 
    5.0 (N=6♀elderly)    
90Kosaki et al.l  5-10 (N=7) 10-25 (N=6)   25-35(N=3) 
91Levy et al.m  2.3 (N=6) 9.4 (N=6) low dose  
   range 1.5-3.1 range 5.3-16.7 
61Ochs et al.  1.9 (N=6♂)n 
   2.5 (N=7♀)n           
64,65Rupp et al.o  8 (N=10)  
48Sennoune et al.p 3 (N=10)q 10-13 (N=22)r 
40Seo et al.s  8-10 (N=38)t     36 (N=12)u   
aBoth carbamazepine and phenytoin induce many metabolic enzymes, but it is believed that they increase 
the N-desmethylclobazam/clobazam ratio by inducing CYP3A4.  Phenytoin may sometimes behave as a 
competitive inhibitor of N-desmethylclobazam metabolism. Phenobarbital may not be an inducer of 
clobazam metabolism (see footnote r).  
bFelbamate is a CYP3A inducer and CYP2C19 inhibitor. 
cThis is an English boy. First TDM values were used in ratio calculations. 
dRatio ranges were not provided. These are Finnish children. The mean N-desmethylclobazam/clobazam 
ratio was 4.2 in patients not taking other antiepileptic drugs (N= 7). The mean ratio was 5.0 in patients 
taking non-inducing antiepileptic drugs (sample size was not described). The mean ratio was 19.9 in 
patients taking inducing antiepileptic drugs (sample size is not described).   
eThese are French volunteers who received 20 mg/day for 28 days. The ratios were calculated using 
concentrations described for day 28. The N-desmethylclobazam/clobazam ratio values were 2.3, 3.0, 3.1, 
3.9, 6.9 and 8.4. 
fThese are Italian children and adults. The table describes mean ratios and, for the upper panel, patients 
who were outliers are described in the line below.  
gRatio ranges were not provided. These are Italian children or adults. Three of 11 controls were taking 
inducers. Eight of the controls had 2 active CYP2C19 alleles and 3 had only 1 active allele.  
hItalian child who was a CYP2C19 PM. 
iItalian child who appeared to be a CYP2C19 PM due to the presence of a CYP2C19 inactive allele (*2) 
and possibly a rare undetected CYP2C19 inactive allele. This patient also appeared to be published as an 
individual case report in another article.57 
jCYP2C19 genotyping was completed in 22 French children taking valproate and clobazam. There were 
18 with 2 active CYP2C19 alleles and 4 with only 1 active allele. All patients with 2 active alleles had N-
desmethylclobazam/clobazam ratios <7.5. All 4 patients with 1 active allele had N-




lJapanese patients who were not CYP2C19 PMs by genotype. Normals were patients who were not 
CYP2C19 PMs and were not taking inducers. The serum concentrations were not trough concentrations. 
Ranges of the N-desmethylclobazam/clobazam ratio are provided.   
mThese are 6 US volunteers who received 20 mg/day for 29 days. A carbamazepine dose of 400 mg/day 
was given from day 16 to day 29. The dose and duration will not allow viewing the induction seen in 
patients taking clinical doses. In the 6 subjects, the baseline versus carbamazepine N-
desmethylclobazam/clobazam ratios were 2.4 vs. 8.5, 1.5 vs. 5.9, 3.1 vs. 10.9, 2.9 vs. 16.7, 1.6 vs. 5.3, 
and 2.2 vs. 9.3. 
nData calculated from an article table. After 22 days on 10 mg/day clobazam, 6 US males had a mean 
trough clobazam concentration of 191 ng/mL and N-desmethylclobazam concentration of 368 ng/mL, 
providing an estimated N-desmethylclobazam/clobazam ratio of 1.9 (368/191=1.9). The article table 
describing 7 US females shows a mean trough clobazam concentration of 253 ng/mL and a mean trough 
N-desmethylclobazam concentration of 637 ng/mL providing an N-desmethylclobazam/clobazam ratio of 
2.5 (637/253=2.5).  
oRatio ranges are not provided. These are Indian volunteers who received 20 mg/day of clobazam for 28 
days. 
pFrench adults. The serum concentrations were not trough; the blood samples were drawn within three 
hours after clobazam dose intake. 
qThese include 9 patients on monotherapy with a mean ratio of 3.3±2.0. This line of the table does not 
include 15 patients on valproate with a mean ratio of 4.2±2.5. 
rRatio ranges are not provided. The number is based on 17 patients on carbamazepine with a mean ratio of 
10.3±5.3, and 5 patients on phenytoin with a mean ratio of 12.8±5.6.  There were 17 patients on 
phenobarbital with a mean ratio of 6.2±2.3 who are not included in this line of the table. 
sJapanese adult and child patients who were genotyped. It is not clear how much the data was influenced 
by inducers.  The serum concentrations were not trough. For each patient, 1 concentration was randomly 
selected from the patient’s available concentrations. Blood samples were drawn within 3-5 hours after 
clobazam dose intake. 
tRatio ranges were not provided. The number is based on 16 patients with 2 active alleles with a mean 
ratio of 7.6±4.6, and 22 patients with 1 active allele with a mean ratio of 9.8±7.9.  
uRatio ranges were not provided.  The number is based on 12 patients with no active alleles with a mean 
ratio of 35.7±16.7.  
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Table 4. Review of articles providing clobazam concentrations (peak or trougha): Clobazam C/D ratiob   
Reference  Normal  Inducersc Felbamated CYP2C19     
     Clobazam C/D ratio        
41Aylett et al.e x kg        66.7 
                    70 kg ideal       0.96 
88Bun et al.f   12.1 (N=6)  
   range 9.8-14.6 
89Contin et al. x kg g 600h (N=22) 300h (N=28) 200h (N=16) 
 70 kg ideal 8.6  4.3  2.9    
22Contin et al. x kg 200-1100 (N=11)i    85.3 (N=1)j & 370.5 (N=1)k   
 70 kg ideal 12-66      1.2           5.3   
70Greenblatt et al.l 11.1 (N=7♂young)   
   16.6 (N=8♀young) 
                28.4 (N=6♂elderly) 
    20.2 (N=6♀elderly)    
90Kosaki et al.m  x kg <1000 (N=7) <1800 (N=6)   <700(N=3) 
 70 kg ideal <14.3  <25.7    <10             
91Levy et al.n  17.7 (N=6) 6.8 (N=6) low dose  
   range 9.9-24.6 range 4.4-11.1 
61Ochs et al.  19.1 (N=6♂)o 
   range 15.6-23.3  
   25.3 (N=7♀)o 
   range 18.7-28.1  
48Sennoune et al. x kg 1030(N=9)p 492-497 (N=22)q 
                70 kg ideal 14.7  7.0-7.1         
aTable 4 includes studies with trough and peak concentrations. The study by Ochs et al.61 suggested major 
variations (by 48%) between clobazam trough and peak concentrations. Similarly, Bun et al.34 presented 
clobazam C/D ratios corrected by weight at trough and peak (3 hours after clobazam dose) points on the 
21st day of clobazam treatment from 6 healthy volunteers and 17 patients (6-32 years old) taking co-
medications. The peak weight-corrected clobazam C/D ratio appeared to be roughly twice as high as the 
trough C/D ratio in both healthy volunteers and patients. Therefore, the use of either peak or trough 
concentrations in different studies may seriously contaminate comparisons of C/D ratios data in this table. 
bMost TDM articles use ng/mL to measure clobazam levels. When using ng/mL for concentration and 
mg/day for dosing, C/D ratio units are (ng × day)/(mL × mg). This is a reasonable approximation and an 
easy measure for clinicians. In strict pharmacological terms, it would be better to transform the clobazam 
concentration to μmol/L and the daily dose to μmol/day. This would make calculations more accurate but 
much harder for clinicians to estimate. According to Patsalos et al.9 1.0 μmol/L is equivalent to 333 
ng/mL for clobazam, and 1.0 μmol/L is equivalent to 349 ng/mL for N-desmethylclobazam. This is a 
minor difference of 5% (349/333=1.05) between both molar transformations on N-desmethylclobazam 
versus clobazam. A 5% error is made when the differences in molecular weights between N-
desmethylclobazam and clobazam are disregarded by calculating C/D ratios using ng/mL. This increases 
the weight of serum N-desmethylclobazam concentrations by 5% more than would be the case if molar 
concentrations were used. Thus avoiding the tedious (and probably confusing for clinicians) molar 
transformations makes a reasonable error of only 5%.  When clobazam TDM studies focus only on adults, 
using this (ng × day)/(mL × mg) unit for C/D ratios is reasonable. When the studies include children, 
there is a need to correct the dose by weight using mg/kg × day, and to make the unit for C/D ratios (ng × 
day×kg)/(mL × mg). Tables 4-6 use an additional way to compare children and adults by transforming 
weight-corrected C/D ratios in children to standardized values in a standard 70-kg individual. 
cBoth carbamazepine and phenytoin induce many metabolic enzymes but it is believed that they increase 
the N-desmethylclobazam/clobazam ratio by inducing CYP3A4.  Phenytoin may sometimes behave as a 
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competitive inhibitor of N-desmethylclobazam metabolism. Phenobarbital may not be an inducer of 
clobazam metabolism (see below footnote r).  
dFelbamate is a CYP3A inducer and CYP2C19 inhibitor. 
eThis is an English boy. First TDM values were used in ratio calculations. 
fThese are French volunteers who received 20 mg/day for 28 days. The ratios were calculated using 
concentrations described for day 28.  
gThese are Italian children and adults.  
hCalculations were made by adding approximations taken from figures. 
iRatio ranges were not provided. These are Italian children or adults. Three of 11 controls were taking 
inducers. Eight of the controls had 2 active CYP2C19 alleles and 3 had only 1 active allele.  
jItalian child who was a CYP2C19 PM. 
kItalian child who appeared to be a CYP2C19 PM due to the presence of a CYP2C19 inactive allele (*2) 
and possibly a rare undetected CYP2C19 inactive allele. This patient also appeared to be published as an 
individual case report in another article.42 
lUS volunteers. 
mJapanese patients who were not CYP2C19 PMs by genotype. Normals were patients who were not 
CYP2C19 PMs and were not taking inducers. The serum concentrations were not trough concentrations. 
nThese are 6 US volunteers who received 20 mg/day for 29 days. A carbamazepine dose of 400 mg/day 
was given from day 16 to day 29. The dose and duration will not allow viewing the induction seen in 
patients taking clinical doses.  
oData calculated from an article table.  After 22 days on 10 mg/day clobazam, 6 US males provided a 
mean trough clobazam concentration of 191 ng/mL (range 156-233) with a clobazam C/D of 19.1 (15.6-
23.3),  and 7 US females provided a mean concentration of 253 ng/mL (range 187-281) with a C/D of 
25.3 (18.7-28.1). 
pThese include 9 patients on monotherapy. There were15 patients on valproate with a mean clobazam C/D 
ratio of 699 (ng ×kg/ml)/(mg/day) that corresponds to 9.99 (ng /ml)/(mg/day) in a hypothetical person of 
70 kg, which is not included in this line of the table.  
qThese include 17 patients on carbamazepine with a mean clobazam C/D ratio of 492 (ng 
×kg/ml)/(mg/day) that corresponds to 7.0 (ng /ml)/(mg /day) in a hypothetical person of 70 kg; and 5 
patients on phenytoin with a mean clobazam C/D ratio of 497 (ng ×kg/ml)/(mg/day) that corresponds to 
7.1 (ng /ml)/(mg/day) in a hypothetical person of 70 kg. There were 17 patients on phenobarbital with a 
mean clobazam C/D ratio of 373 (ng ×kg/ml)/(mg/day) that corresponds to 5.3 (ng /ml)/(mg/day) in a 
hypothetical person of 70 kg, which is not included in this line of the table.  
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Table 5. Review of articles providing clobazam concentrations: N-desmethylclobazam C/D ratioa   
Reference  Normal  Inducersb Felbamatec CYP2C19 PM      
                          N-desmethylclobazam C/D ratio       
41Aylett et al.d x kg        16400 
                    70 kg ideal       234 
88Bun et al.e  58.1 (N=6)  
   range 28.1-122.1 
89Contin et al.f x kg 2000g (N=22) 3000g (N=28) 7000g (N=16) 
 70 kg ideal 28.6  42.9  100    
22Contin et al. x kg   200-10000 (N=11)h    17707 (N=1)i & 28865 (N=1)j   
 70 kg ideal 2.9-143      253                    409.5   
70Greenblatt et al.k 16.4 (N=7♂young)   
   71.5 (N=8♀young) 
               393.2 (N=6♂elderly) 
   101.7 (N=6♀elderly)    
90Kosaki et al.l x kg <4000 (N=7) <13000 (N=6)   8000-17000(N=3) 
 70 kg ideal <57.1  <185.7    114.3-242.9             
91Levy et al.m  42.5 (N=6) 61.3 (N=6) low dose  
   range 14.8-77 range 25.9-88.1 
61Ochs et al.  36.8 (N=6♂)n 
   range 26.8-63.5  
   63.7 (N=7♀)n 
   range 29.0-118.6o  
48Sennoune et al. x kg  2974(N=9)p 5066-5830 (N=22)q 
                70 kg ideal  42.5  72.4-82.3        
aSee footnote b on table 4 for clarification about units. 
bBoth carbamazepine and phenytoin induce many metabolic enzymes but it is believed that they increase 
the N-desmethylclobazam/clobazam ratio by inducing CYP3A4.  Phenytoin may sometimes behave as a 
competitive inhibitor of N-desmethylclobazam metabolism. Phenobarbital may not be an inducer of 
clobazam metabolism (see below footnote r).  
cFelbamate is a CYP3A inducer and CYP2C19 inhibitor. 
dThis is an English boy. First TDM values were used in ratio calculations. 
eThese are French volunteers who received 20 mg/day for 28 days. The ratios were calculated using 
concentrations described for day 28. The N-desmethylclobazam/clobazam ratio values were 2.3, 3.0, 3.1, 
3.9, 6.9 and 8.4. 
fThese are Italian children and adults. This line of the table describes mean ratios.  
gCalculations were made by adding approximations taken from figures. 
hRatio ranges were not provided. These are Italian children or adults. Three of 11 controls were taking 
inducers. Eight of the controls had 2 active CYP2C19 alleles and 3 had only 1 active allele.  
iItalian child who was a CYP2C19 PM. 
jItalian child who appeared to be a CYP2C19 PM due to the presence of a CYP2C19 inactive allele (*2) 
and possibly a rare undetected CYP2C19 inactive allele. This patient also appeared to be published as an 
individual case report in another article.42 
kUS volunteers. 
lJapanese patients who were not CYP2C19 PMs by genotype. Normals were patients who were not 
CYP2C19 PMs and were not taking inducers. The serum concentrations were not trough concentrations. 
mThese are 6 US volunteers who received 20 mg/day for 29 days. A carbamazepine dose of 400 mg/day 
was given from day 16 to day 29. The dose and duration will not allow viewing the induction seen in 
patients taking clinical doses.  
nData calculated from an article table that described that after 22 days on 10 mg/day clobazam, 6 US 
males provided a mean trough N-desmethylclobazam concentration of 368 ng/mL (range 268-635) with 
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an N-desmethylclobazam C/D of 36.8 (26.8-63.5), and 7 US females provided a mean concentration of 
637 ng/mL (range 290-1186) with a C/D of 63.7 (29.0-118.6).  
oThis high range in US female subjects may be compatible with at least one of the females being a 
CYP2C19 PM. 
pThese include 9 patients on monotherapy. There were15 patients on valproate with a mean N-
desmethylclobazam C/D ratio of 2638 (ng ×kg/ml)/(mg/day) that corresponds to 37.7 (ng /ml)/(mg/day) 
in a hypothetical person of 70 kg, which is not included in this line of the table.  
qThese include 17 patients on carbamazepine with a mean N-desmethylclobazam C/D ratio of 5066 (ng 
×kg/ml)/(mg/day) that corresponds to 72.4 (ng /ml)/(mg /day) in a hypothetical person of 70 kg; and 5 
patients on phenytoin with a mean clobazam C/D ratio of 5830 (ng ×kg/ml)/(mg/day) that corresponds to 
82.3 (ng /ml)/(mg/day) in a hypothetical person of 70 kg. There were 17 patients on phenobarbital with a 
mean N-desmethylclobazam C/D ratio of 2037 (ng ×kg/ml)/(mg/day) that corresponds to 29.1 (ng 




Table 6. Review of articles providing clobazam concentrations: Total C/D ratioa     
Reference  Normal  Inducersb Felbamatec CYP2C19 PM      
                          Total (clobazam+N-desmethylclobazam) C/D ratio    
41Aylett et al.d x kg        16467 
                    70 kg ideal       235 
88Bun et al.e   70.2 (N=6)  
   range 39.2-136.7 
22Contin et al. x kg       1792 (N=1)f & 29036 (N=1)g   
 70 kg ideal       254            415   
70Greenblatt et al.h 27.5 (N=7♂young)   
   88.1 (N=8♀young) 
               421.6 (N=6♂elderly) 
   121.9 (N=6♀elderly)    
91Levy et al.i  60.2 (N=6) 68.1 (N=6) low dose  
   range 24.7-102 range 30.3-96.2        
61Ochs et al.  55.9 (N=6♂)j 
   89.0 (N=7♀)j,k          
aSee footnote b on table 4 for clarification about units. 
bBoth carbamazepine and phenytoin induce many metabolic enzymes but it is believed that they increase 
the N-desmethylclobazam/clobazam ratio by inducing CYP3A4.  Phenytoin may sometimes behave as a 
competitive inhibitor of N-desmethylclobazam metabolism. Phenobarbital may not be an inducer of 
clobazam metabolism (see footnote r).  
cFelbamate is a CYP3A inducer and CYP2C19 inhibitor. 
dThis is an English boy. First TDM values were used in ratio calculations. 
eThese are French volunteers who received 20 mg/day for 28 days. The ratios were calculated using 
concentrations described for day 28.  
fItalian child who was a CYP2C19 PM. 
gItalian child who appeared to be a CYP2C19 PM due to the presence of a CYP2C19 inactive allele (*2) 
and possibly a rare undetected CYP2C19 inactive allele. This patient also appeared to be published as an 
individual case report in another article.42 
hUS volunteers. 
iThese are six US volunteers who received 20 mg/day for 29 days. A carbamazepine dose of 400 mg/day 
was given from day 16 to day 29. The dose and duration will not allow viewing the induction seen in 
patients taking clinical doses.  
jData calculated from an article table describing that, after 22 days on 10 mg/day clobazam, 6 US males 
had a mean trough clobazam concentration of 191 ng/mL and a mean  N-desmethylclobazam 
concentration of 368 ng/mL, providing a mean total C/D ratio of  55.9 [(191+368)/10=55.9]. Seven US 
females had a mean trough clobazam concentration of 253 ng/mL and  a mean trough N-
desmethylclobazam concentration of 637 ng/mL, providing a mean total C/D ratio of 89.0 
[(253+637)/10=89.0].  





Table 7. Review of articles providing clobazam area under the curve (AUC) values.a    
Reference  Control  Ketoconazole Omeprazole  Carbamazepine       Phenytoin  
          N-desmethylclobazam AUC/clobazam  AUC      
92Jawad et al.b  1.5      6.2  18.8  
   range 1.0-8.8      range 4.3-8.8 range 16.6-20.9 
33Walzer et al.c  1.60  1.22d    
33Walzer et al.e  1.31    1.55f       
     Clobazam AUC (µg/l)×h)      
92Jawad et al.b  14,226      5,916g  5,941h 
33Walzer et al.c    4,360  6,432i    
33Walzer et al.e    4,239    5,938j       
                          N-desmethylclobazam AUC (µg/l)×h)     
92Jawad et al.b  21,227      35,241k  111,413l 
33Walzer et al.c    6,987  7,851m    
33Walzer et al.e    5,549    9,176n       
                          Clobazam+N-desmethylclobazam AUC (µg/l)×h)     
92Jawad et al.b  35,453      41,157o  117,355p 
33Walzer et al.c  11,347  14,283q   
33Walzer et al.e    9,788    15,114r       
aThis AUC data from single-dose studies with different designs cannot be compared across studies, but 
AUC parameters from each study can be used to provide ratios reflecting drug clearance.  Single-dose 
studies describing clobazam and N-desmethylclobazam AUCs can be used to estimate an N-
desmethylclobazam AUC/clobazam AUC ratio that supplements information from the N-
desmethylclobazam/clobazam ratio from TDM studies. Single-dose studies describing clobazam AUC 
can help to supplement information on the clobazam C/D ratio from TDM studies. Single-dose studies 
describing N-desmethylclobazam AUC can help to supplement information on the desmethylclobazam 
C/D ratio from TDM studies. And single-dose studies describing both clobazam and N-
desmethylclobazam AUCs can help to supplement information on the total C/D ratios from TDM studies. 
bThis study compared clobazam after a single dose in 6 controls with 6 adult epileptic patients on stable 
medication for 3 months. Four of the 6 patients were taking only carbamazepine and 2 were taking both 
carbamazepine and phenytoin. 
cThis study in 17 patients taking 10 mg/day of clobazam provided a baseline AUC and an AUC after 400 
mg/day of ketoconazole for 6 days.  
dThe ratio between ketoconazole and baseline was 1.22/1.60=0.76 or a 24% decrease. 
eThis study in 18 patients taking 10 mg/day of clobazam provide a baseline AUC and an AUC after 40 
mg/day of omeprazole for 6 days.  
fThe ratio between omeprazole and baseline was 1.55/1.31=1.18 or an 18% increase. 
gThe ratio between carbamazepine and controls was 5916/14226=0.42 or a 58% decrease. 
hThe ratio between phenytoin and controls was 5941/14226=0.42 or a 58% decrease. 
iThe ratio between ketoconazole and baseline was 6432/4360=1.48 or a 48% increase. 
jThe ratio between omeprazole and baseline was 5938/4239=1.40 or a 40% increase. 
kThe ratio between carbamazepine and controls was 35241/21227=1.66 or a 66% increase. 
lThe ratio between phenytoin and controls was 111413/21227=5.24 or a 424% increase 
mThe ratio between ketoconazole and baseline was 7851/6987=1.12 or a 12% increase. 
nThe ratio between omeprazole and baseline was 9176/5549=1.65 or a 65% increase. 
oThe ratio between carbamazepine and controls was 41157/35453=1.16 or a 16% increase. 
pThe ratio between phenytoin and controls was 117355/35453=3.31 or a 231% increase. 
qThe ratio between ketoconazole and baseline was 14283/11347=1.26 or a 26% increase. 
rThe ratio between omeprazole and baseline was 15114/9788=1.54 or a 54% increase. 
